glp 1 powerpoint presentation PPT - Improved Cardiovascular Health with GLP-1 Agonists PPT - GLP-1 Receptor Agonists

This combination of increased usage and expanded state coverage has increased Medicaid spending on GLP-1s for obesity to more than $500 million in October 2024 alone, with total expenditures reaching $3.5 billion over the past 12 months

Document past trials, showing clear records of prior treatments

The FDA has also approved it for overweight and obesity in both adults and adolescents

Please note that n numbers are for the number of patients for whom HR data were available bpm beats per minute, HR heart rate, LS least squares, SE standard error, T2DM type 2 diabetes mellitus A second head-to-head comparison trial between lixisenatide and liraglutide was performed in 60 subjects with T2DM [18]